Abstract
Background
Younger women (aged 18–44 years) diagnosed with breast cancer often face more aggressive tumors, higher treatment intensity, and lower survival rates than older women. In this study, we estimated incident breast cancer costs by stage at diagnosis and by race for younger women enrolled in Medicaid.
Methods
We analyzed cancer registry data linked to Medicaid claims in North Carolina from 2003 to 2008. We used Surveillance, Epidemiology, and End Results (SEER) Summary 2000 definitions for cancer stage. We split breast cancer patients into two cohorts: a younger and older group aged 18–44 and 45–64 years, respectively. We conducted a many-to-one match between patients with and without breast cancer using age, county, race, and Charlson Comorbidity Index. We calculated mean excess total cost of care between breast cancer and non-breast cancer patients.
Results
At diagnosis, younger women had a higher proportion of regional cancers than older women (49 vs. 42%) and lower proportions of localized cancers (44 vs. 50%) and distant cancers (7 vs. 9%). The excess costs of breast cancer (all stages) for younger and older women at 6 months after diagnosis were $37,114 [95% confidence interval (CI) = $35,769–38,459] and $28,026 (95% CI = $27,223–28,829), respectively. In the 6 months after diagnosis, the estimated excess cost was significantly higher to treat localized and regional cancer among younger women than among older women. There were no statistically significant differences in excess costs of breast cancer by race, but differences in treatment modality were present among younger Medicaid beneficiaries.
Conclusions
Younger breast cancer patients not only had a higher prevalence of late-stage cancer than older women, but also had higher within-stage excess costs.
Similar content being viewed by others
References
United States Cancer Statistics: 1999–2012 incidence and mortality web-based report. www.cdc.gov/uscs
Anders CK, Johnson R, Litton J, Phillips M, Bleyer A (2009) Breast cancer before age 40 years. Semin Oncol 36(3):237–249
Lee HB, Han W (2014) Unique features of young age breast cancer and its management. J Breast Cancer 17(4):301–307
Maggard MA, O’Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY (2003) Do young breast cancer patients have worse outcomes? J Surg Res 113(1):109–113
Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE 4(11):e7695
Howard-Anderson J, Ganz PA, Bower JE, Stanton AL (2012) Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 104(5):386–405
Trivers KF, Fink AK, Partridge AH, Oktay K, Ginsburg ES, Li C, Pollack LA (2014) Estimates of young breast cancer survivors at risk for infertility in the U.S. Oncologist 19(8):814–822
Brown DS, Trogdon JG, Ekwueme DU, Chamiec-Case L, Guy GP, Tangka FK, Li C, Trivers KF, Rodriguez JL (2016) Health state utility impact of breast cancer in US women aged 18–44 years. Am J Prev Med 50(2):255–261
Trogdon JG, Ekwueme DU, Chamiec-Case L, Guy GP (2016) Breast cancer in young women: health state utility impacts by race/ethnicity. Am J Prev Med 50(2):262–269
Allaire BT, Ekwueme DU, Guy GP, Li C, Tangka FK, Trivers KF, Sabatino SA, Rodriguez JL, Trogdon JG (2016) Medical care costs of breast cancer in privately insured women aged 18–44 years. Am J Prev Med 50(2):270–277
Ekwueme DU, Allaire BT, Guy GP, Arnold S, Trogdon JG (2016) Treatment costs of breast cancer among younger women aged 19–44 years enrolled in Medicaid. Am J Prev Med 50(2):278–285
Ekwueme DU, Trogdon JG, Khavjou OA, Guy GP (2016) Productivity costs associated with breast cancer among survivors aged 18–44 years. Am J Prev Med 50(2):286–294
Baker LC, Royalty AB (2000) Medicaid policy, physician behavior, and health care for the low-income population. J Hum Resour 35(3):22
Halpern MT, Ward EM, Pavluck AL, Schrag NM, Bian J, Chen AY (2008) Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol 9(3):222–231
Shi R, Taylor H, McLarty J, Liu L, Mills G, Burton G (2015) Effects of payer status on breast cancer survival: a retrospective study. BMC Cancer 15:211
Lipscomb J, Fleming ST, Trentham-Dietz A, Kimmick G, Wu XC, Morris CR, Zhang K, Smith RA, Anderson RT, Sabatino SA et al (2016) What predicts an advanced-stage diagnosis of breast cancer? sorting out the influence of method of detection, access to care, and biologic factors. Cancer Epidemiol Biomark Prev 25(4):613–623
O’Malley CD, Shema SJ, Clarke LS, Clarke CA, Perkins CI (2006) Medicaid status and stage at diagnosis of cervical cancer. Am J Public Health 96(12):2179–2185
Subramanian S, Trogdon J, Ekwueme DU, Gardner JG, Whitmire JT, Rao C (2011) Cost of breast cancer treatment in Medicaid: implications for state programs providing coverage for low-income women. Med Care 49(1):89–95
IOM (2001) Coverage matters: insurance and health Care. National Academy of Press, Washington, DC
Hassett MJ, Schymura MJ, Chen K, Boscoe FP, Gesten FC, Schrag D (2016) Variation in breast cancer care quality in New York and California based on race/ethnicity and Medicaid enrollment. Cancer 122(3):420–431
Grant SR, Walker GV, Koshy M, Shaitelman SF, Klopp AH, Frank SJ, Pugh TJ, Allen PK, Mahmood U (2015) Impact of insurance status on radiation treatment modality selection among potential candidates for prostate, breast, or gynecologic brachytherapy. Int J Radiat Oncol Biol Phys 93(5):968–975
Mobley LR, Subramanian S, Tangka FK, Hoover S, Wang J, Hall IJ, Singh SD (2016) Breast cancer screening among women with Medicaid, 2006–2008: a multilevel analysis. J Racial Ethn Health Dispar 4(3):446–454
Haji-Jama S, Gorey KM, Luginaah IN, Zou G, Hamm C, Holowaty EJ (2016) Disparities report: disparities among minority women with breast cancer living in impoverished areas of California. Cancer Control 23(2):157–162
Akinyemiju TF, Vin-Raviv N, Chavez-Yenter D, Zhao X, Budhwani H (2015) Race/ethnicity and socio-economic differences in breast cancer surgery outcomes. Cancer Epidemiol 39(5):745–751
Shankaran V, Jolly S, Blough D, Ramsey SD (2012) Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol 30(14):1608–1614
Jagsi R, Pottow JA, Griffith KA, Bradley C, Hamilton AS, Graff J, Katz SJ, Hawley ST (2014) Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol 32(12):1269–1276
Khanna R, Madhavan SS, Bhanegaonkar A, Remick SC (2011) Prevalence, healthcare utilization, and costs of breast cancer in a state Medicaid fee-for-service program. J Women’s Health 20(5):739–747
Sabik LM, Tarazi WW, Bradley CJ (2015) State Medicaid expansion decisions and disparities in women’s cancer screening. Am J Prev Med 48(1):98–103
Bradley CJ, Given CW, Roberts C (2002) Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94(7):490–496
Segel JE (2006) Cost-of-illness studies—a primer. RTI-UNC Center of Excellence in Health Promotion Economics, Chapel Hill, pp 1–39
Blumen H, Fitch K, Polkus V (2016) Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits 9(1):23
Meyer AM, Olshan AF, Green L, Meyer A, Wheeler SB, Basch E, Carpenter WR (2014) Big data for population-based cancer research: the integrated cancer information and surveillance system. N C Med J 75(4):265–269
Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML (2008) Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 100(12):888–897
Reck J, Yalowich R (2016) Understanding medicaid claims and encounter data and their use in payment reform. In: National Academy for State Health Policy, pp 1–6
Primary Care Case Management in North Carolina .https://www.cga.ct.gov/2008/rpt/2008-R-0622.htm
Iacus SM, King G, Porro G (2011) Causal inference without balance checking: Coarsened exact matching. Polit Anal 20:1–24
Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251
Iacus SM, King G, Porro G (2009) CEM: software for coarsened exact matching. J Statis Softw 30:1–27
Analysis USBoE: Table 1.1.9. Implicit Price Deflators for Gross Domestic Product. In
Reeder-Hayes KE, Meyer AM, Dusetzina SB, Liu H, Wheeler SB (2014) Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer. Breast Cancer Res Treat 145(3):743–751
Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML (2011) Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 103(2):117–128
Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML (2008) Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 100(9):630–641
Khanna R, Madhavan SS, Bhanegaonkar A, Remick SC (2011) Prevalence, healthcare utilization, and costs of breast cancer in a state Medicaid fee-for-service program. J Women’s Health 20(5):739–747
Bradley CJ, Given CW, Roberts C (2002) Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94(7):490–496
Roetzheim RG, Gonzalez EC, Ferrante JM, Pal N, Van Durme DJ, Krischer JP (2000) Effects of health insurance and race on breast carcinoma treatments and outcomes. Cancer 89(11):2202–2213
Irwin DE, Masaquel A, Johnston S, Barnett B (2016) Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries. J Med Econ 19(11):1027–1033
Ekwueme DU, Trogdon JG (2016) The economics of breast cancer in younger women in the U.S.: the present and future. Am J Prev Med 50(2):249–254
Breast Cancer Education and Awareness Requires Learning Young (EARLY) Act of 2009 H.R. 1740 S. In
Acknowledgements
Work on this study was supported by the Integrated Cancer Information and Surveillance System (ICISS), UNC Lineberger Comprehensive Cancer Center with funding provided by the University Cancer Research Fund (UCRF) via the State of North Carolina.
Funding
This research was supported by contract number 200-2008-27958 Task Order 38 from the Centers for Disease Control and Prevention.
Disclaimer
The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Dr. Trogdon declares that he has no conflict of interest. Dr. Ekwueme declares that he has no conflict of interest. Ms. Poehler declares that she has no conflict of interest. Ms. Thomas declares that he has no conflict of interest. Mr. Allaire declares that he has no conflict of interest.
Ethical approval
The study was reviewed by the UNC Institutional Review Board and deemed to not involve human subjects research.
Appendix
Appendix
See Table 5.
Rights and permissions
About this article
Cite this article
Trogdon, J.G., Ekwueme, D.U., Poehler, D. et al. Medical costs of treating breast cancer among younger Medicaid beneficiaries by stage at diagnosis. Breast Cancer Res Treat 166, 207–215 (2017). https://doi.org/10.1007/s10549-017-4386-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-017-4386-2